Emerging concepts for the in vitro derivation of murine haematopoietic stem and progenitor cells

Garcia-Alegria, Eva; Menegatti, Sara; Batta, Kiran; Cuvertino, Sara; Florkowska, Magdalena; Kouskoff, Valerie
November 2016
FEBS Letters;Nov2016, Vol. 590 Issue 22, p4116
Academic Journal
Well into the second decade of the 21st century, the field of regenerative medicine is bursting with hopes and promises to heal young and old. The bespoken generation of cells is thought to offer unprecedented cures for a vast range of diseases. Haematological disorders have already benefited tremendously from stem cell therapy in the form of bone marrow transplantation. However, lack of compatible donors often means that patients remain on transplantation waiting lists for too long. The in vitro derivation of haematopoietic stem cells offers the possibility to generate tailor-made cells for the treatment of these patients. Promising approaches to generate in vitro-derived blood progenitors include the directed differentiation of pluripotent stem cells and the reprogramming of somatic cells.


Related Articles

  • Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies. Ratcliffe, Elizabeth; Glen, Katie E.; Naing, May Win; Williams, David J. // British Medical Bulletin;Dec2013, Vol. 108 Issue 1, p73 

    Background Apart from haematopoietic stem cell transplantation for haematological disorders many stem cell-based therapies are experimental. However, with only 12 years between human embryonic stem cell isolation and the first clinical trial, development of stem cell products for regenerative...

  • Emerging Stem Cell Therapies: Treatment, Safety, and Biology. Joel Sng; Thomas Lufkin // Stem Cells International;2012, p1 

    Stem cells are the fundamental building blocks of life and contribute to the genesis and development of all higher organisms. The discovery of adult stem cells has led to an ongoing revolution of therapeutic and regenerative medicine and the proposal of novel therapies for previously terminal...

  • Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients. Im, H J; Koh, K N; Suh, J K; Lee, S W; Choi, E S; Jang, S; Kwon, S W; Park, C-J; Seo, J J // Bone Marrow Transplantation;Feb2015, Vol. 50 Issue 2, p225 

    We evaluated the feasibility of T-cell-depleted haploidentical hematopoietic SCT (HHCT) in pediatric patients. Between July 2008 and January 2013, 28 patients underwent ex vivo T-cell-depleted HHCT; 9 had hematologic malignancy, 18 had nonmalignant hematologic disease, and 1 had refractory...

  • Human Bone Marrow Mesenchymal Stem Cells: A Systematic Reappraisal Via the Genostem Experience. Charbord, Pierre; Livne, Erella; Gross, Gerhard; Häupl, Thomas; Neves, Nuno M.; Marie, Pierre; Bianco, Paolo; Jorgensen, Christian // Stem Cell Reviews & Reports;Mar2011, Vol. 7 Issue 1, p32 

    Genostem (acronym for "Adult mesenchymal stem cells engineering for connective tissue disorders. From the bench to the bed side") has been an European consortium of 30 teams working together on human bone marrow Mesenchymal Stem Cell (MSC) biological properties and repair capacity. Part of...

  • Impact of ATG Dose on the Outcome of Patients Undergoing Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Cornillon, Jérôme; Balsat, Marie; Cabrespine, aurélie; Tavernier-Tardy, Emmanuelle; Hermet, Eric; Mulliez, aurélien; augeul-Meunier, Karine; Guyotat, Denis; Bay, Jacques-Olivier // Acta Haematologica;Nov2016, Vol. 136 Issue 4, p193 

    Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often proposed for patients with comorbidities. To enhance engraftment and limit graft-versus-host disease (GVHD), antithymoglobulin (ATG) is usually used. However, the dose needed remains...

  • Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies. Pont, M. J.; Honders, M. W.; Kremer, A. N.; van Kooten, C.; Out, C.; Hiemstra, P. S.; de Boer, H. C.; Jager, M. J.; Schmelzer, E.; Vries, R. G.; Al Hinai, A. S.; Kroes, W. G.; Monajemi, R.; Goeman, J. J.; Böhringer, S.; Marijt, W. A. F.; Falkenburg, J. H. F.; Griffioen, M. // PLoS ONE;5/12/2016, Vol. 11 Issue 5, p1 

    Cellular immunotherapy has proven to be effective in the treatment of hematological cancers by donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation and more recently by targeted therapy with chimeric antigen or T-cell receptor-engineered T cells. However, dependent...

  • Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells. Wai Feng Lim; Tomoko Inoue-Yokoo; Keai Sinn Tan; Lai, Mei I.; Daisuke Sugiyama // Stem Cell Research & Therapy;2013, Vol. 4 Issue 3, p1 

    Pluripotent stem cells, both embryonic stem cells and induced pluripotent stem cells, are undifferentiated cells that can self-renew and potentially differentiate into all hematopoietic lineages, such as hematopoietic stem cells (HSCs), hematopoietic progenitor cells and mature hematopoietic...

  • Busulfan.  // Reactions Weekly;9/29/2012, Issue 1421, p15 

    The article describes several cases of patients with haematological malignancies who developed late-onset veno-occlusive disease (VOD) or sinusoidal obstruction (SOS) after receiving treatment with busulfan and haemotopoietic cell transplant (HCT). All patients underwent conditioning...

  • Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. Akan, Hamdi; Antia, Vistasp P.; Kouba, Michal; Sinkó, János; Tănase, Alina Daniela; Vrhovac, Radovan; Herbrecht, Raoul // Journal of Antimicrobial Chemotherapy (JAC);Nov2013 Supplement, Vol. 68 Issue suppl_3, piii5 

    Invasive fungal disease (IFD), predominantly aspergillosis, is associated with significant morbidity and mortality in immunocompromised patients, especially those with haematological malignancies and recipients of allogeneic haematopoietic stem cell transplantation. There has been a great deal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics